Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed at $560.93 up 0.43% from its previous closing price of $558.52. In other words, the price has increased by $0.43 from its previous closing price. On the day, 1.14 million shares were traded.
Ratios:
For a deeper understanding of Regeneron Pharmaceuticals, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.52. For the most recent quarter (mrq), Quick Ratio is recorded 4.03 and its Current Ratio is at 4.93. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On February 05, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $762 to $834.
UBS Downgraded its Buy to Neutral on January 16, 2025, whereas the target price for the stock was revised from $1130 to $738.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.28, and their Forward P/E ratio for the next fiscal year is 14.19. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.30 while its Price-to-Book (P/B) ratio in mrq is 2.07.
Stock Price History:
Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $525.99. The 50-Day Moving Average of the stock is -10.54%, while the 200-Day Moving Average is calculated to be -32.58%.
Shares Statistics:
A total of 106.40M shares are outstanding, with a floating share count of 104.06M. Insiders hold about 3.61% of the company’s shares, while institutions hold 88.61% stake in the company.
